Professional Documents
Culture Documents
Abstract Introduction
Abstract Introduction
Methodology:
Thirty (30) GNM students were selected to conduct this study at
the Ancillary Medical Training School, Shireenbagh, Srinagar,
Kashmir. Quantitative approach was adopted. A pre-
experimental one group pre-test post-test design was used in the
present study to accomplish the objectives. Simple random
sampling technique was used for the selection of 30 GNM
students from the accessible population. The prepared tool
(structured knowledge questionnaire and interview) and the
intervention (structured teaching program) was validated by a
panel of experts. Pre-testing of the tool and intervention was
done to check for the clarity and feasibility. Pilot study was
conducted to assess the feasibility of the study. The main study
was conducted from. Data was collected by the administering
structured knowledge questionnaire and interview. After
collecting data, structured teaching program to the subjects on
the 7th post-test was conducted by using same structured
knowledge questionnaire and interview. The collected data was
analyzed by using descriptive and inferential statistics.
Results:
Conclusion:
Key words: Impact, Structured Teaching Program,
Knowledge, Corona Virus disease (COVID-19), GNM Students.
CONTENTS
Chapter Title Page No.
I Introduction 01-18
Background of the study
Need for the study
Statement of the problem
Objectives of the study
Hypothesis
Operational definitions
Assumptions
Delimitations
Conceptual frame work
Summary
II Review of literature 19-30
Incidence and prevalence of Corona Virus Disease
(COVID-19)
Clinical manifestation of Corona Virus Disease
(COVID-19)
Transmission of Corona Virus Disease (COVID-19)
Preventive measures and treatment of Corona Virus
Disease (COVID-19)
Vaccines for Corona Virus Disease (COVID-19)
Impact of structured teaching program
Summary
III Methodology
Research approach
Research design
Setting of the study
Variables
Population
Sample and sampling techniques
Criteria for sample selection
Data collection instrument
Development of the tool (structured questionnaire
and interview)
Description of the tool
Scoring pattern/ criteria measure for the knowledge
Preparation of the Blueprint
Content validity of the tool and intervention
Reliability of the tool
Tool try out
Development of final draft of the tool
Development of the intervention
Pilot study
Ethical consideration
Method of data collection
Plan for data analysis
Summary
IV Analysis and interpretation
V Discussion
VI Summary of the major finding, conclusion,
nursing implications and recommendations
Reverences
Annexures
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
3
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
Patho-physiology [07]
4
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
5
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
COVID-19 affects different people in different ways. Most
infected people will develop mild to moderate illness and
recover without hospitalization. Most common symptoms:
fever, dry cough, tiredness. Less common symptoms: aches
and pains, sore throat, diarrhea, conjunctivitis, headache,
loss of taste or smell, a rash on skin, or discoloration of
fingers or toes. Serious symptoms: difficulty breathing or
shortness of breath, chest pain or pressure, loss of speech or
movement.
According to researchers in China, these were the most
common symptoms among people who had COVID-19:
Fever (99%), fatigue (70%), cough (59%), lack of appetite
(40%), body aches (35%), shortness of breath (31%), and
mucus/phlegm (27%).
Some people who are hospitalized for COVID-19 have also
had dangerous blood clots, including in their legs, lungs,
and arteries. [08]
4
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
those with other underline diseases (immune-compromised)
are more prone to developing infections and complications
and this may lead to fatality particularly in older ones.
Furthermore, it has been proven that while those who have
blood group O may be protected against severe COVID-19,
individuals having blood group A are more susceptible to
severe COVID-19 infection. This is as a result of low ACE
present on blood group O that can be used by SARS-CoV-2
as a receptor for entry. Underline health conditions;
Hypertension, diabetes, cardiovascular disease, chronic
respiratory disease, chronic kidney disease, Cancer, COPD,
asthma, smoking, obesity, pre existing medical conditions
have also been suggested as a risk for COVID -19
complication, health care workers are at high risk of
COVID -19 infection because of more frequent exposure to
covid-19 cases. [09]
COVID-19 diagnostic testing is done to find out if someone
is currently infected with SARS-COV-2, the virus that
causes Corona Virus Disease (COVID-19). There are
different types of diagnostic tests available. Some
diagnostic tests used to detect infection and others detect an
immune response. Testing plays an important role in public
health response to COVID-19.The various diagnostic tests
for covid-19 include: Molecular testing (NAAT/RT-PCR),
serology testing [detect antibodies against COVID-19
antigen; IgM, IgG, IgA], laboratory examination, Imaging
[chest x-ray examination, chest computed tomography,
lung ultrasound]. [10]
Some people -- about 1 in 6 -- will have complications,
including some that are life-threatening. Many of these
complications may be caused by a condition known as
cytokine release syndrome or a cytokine storm. This is
when an infection triggers your immune system to flood the
5
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
bloodstream with inflammatory proteins called cytokines.
They can kill tissue and damage your organs, including the
lungs, heart, and kidneys. COVID-19 complications may
include the following: Acute respiratory failure,
pneumonia, acute respiratory distress syndrome (ARDS),
acute liver injury, acute cardiac injury, secondary infection,
acute kidney injury, septic shock, disseminated
intravascular coagulation, multisystem inflammatory
syndrome in children, chronic fatigue, rhabdomyolysis. [11]
There is currently no for an infection with the new corona
virus. However, many treatments and vaccines are
currently under study. On October 22, 2020, the Food and
Drug Administration (FDA) approved its first COVID-19
treatment, the medication Remdesivir (veklury). It is
available by prescription for people age 12 years and older
who have been hospitalized. It is administered as an
intravenous infusion. In November 2020, the FDA also
grotal the Emergency Use Authorization (EUAs) to
monoclonal antibody medications. Monoclonal antibodies
are human-made proteins that help to fight off foreign
made substances such as viruses. These medications are:
Bamlanivimab, Casirivimab and Imdevimab, which must
be administered together.
Like Remdesivir, they are also administered by IV infusion
and intended for people ages 12 years & older. These
medications are used for outpatient therapy. [12]
The world is in the midst of a Covid-19 pandemic.
Vaccines save millions of lives each year. Vaccines work
by training and preparing the body’s natural defenses - the
immune system to recognize and fight off the viruses and
bacteria they target. If the body is exposed to those disease-
6
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
causing germs later, the body is immediately ready to
destroy them thereby preventing illness. (2021). [13]
Russia as the first country to grant regulatory approval to
Covid-19 vaccine named “SPUTNIK-V”.The Phase 1
human trials started in 17th June. Phase 2 trials were started
on July 13 in Gamaleya Institute announced it complete
clinical trial on August 2. (August 12-2020). [14]
The OXFORD-ASTRAZENECA vaccine known as Covi-
Shield in India is being produced locally by the Serum
Institute of India, the World’s largest vaccine manufacturer
(Cova-Vaxin). (Jan 3 2021). [15]
The UK is the first country in world to start using the Pfizer
vaccine. Name: BNT162b2. Manufacturer: PFIZER, Inc
and BioNTech. Type of vaccine: mRNA. Number of shots:
2 shots, 21 days apart and is given in the muscle of upper
arm. (8 December 2020). [16]
As of November 2020, the moderns COVID-19 candidate
mRNA 1273, has shown preliminary evidence of 94%
efficacy of preventing COVID-19 disease. It was
authorized for use In Canada on December 23 2020 as well
as in European Union on January 6, 2021 subsequently the
mRNA 1273 was authorized in the United Kingdom on 8
January 2021. .it is developed by the National Institute
of Allergy and infectious Disease. (2021 Jan 8). [17]
Novavax is a Maryland based Bio-Technology firm that is
taking a traditional approach to a developing a vaccine
against the corona virus disease (NVX COV 2373). The
Novavax vaccine uses a custom made Spike Protein. The
protein is combined with Novavaxe’s matrix adjuvant
which is important enhancing the immune responses
elicited by the protein antigen. (2020). [18]
7
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
Ad 26.Cov2.S also known as Johnson and Johnson
COVID-19 Vaccines and Janssen COVID-19 Vaccine is a
vaccine candidate developed by Janssen pharmaceuticals
(Johnson, Johnson) and Beth Isract Deacons Medical
Centre (BIDMC). (13 Jan 2021). [19]
Clinical management of COVID-19 disease includes
infection prevention and control measures and supportive
care (including supplemental oxygen and mechanical
ventilator support).
Mild case management includes isolation, symptomatic
management, supportive care, adequate nutrition and
appropriate rehydration. Tab Hydroxychloroquine for those
patients have high risk features and antipyretics for fever
and -pain.
Moderate case management includes oxygen support
(target spo2 92-96%), daily 12 leads ECG, clinical
investigation (CBC, KFT, CRP, D-dimer), Tab
Hydroxychloroquine 400mg (BD) on Ist day followed by
200 mg for next four days, Methylprednisolone, low
molecular weight heparin and control of comorbid
conditions.
Severe case management includes early supportive therapy
and monitoring, supplemental oxygen therapy (5ltr/min),
management of hypoxemic respiratory failure and ARSD,
management of septic shock. [20]
Preventive measures are the current strategy to limit the
spread of cases. Preventive strategies are focused on the
isolation of patients and careful Infection Control,
including appropriate measures to be adopted during the
diagnosis & the provision of clinical care to an infected
patient. For instance, droplet, Contact, & airborne
8
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
precautions should be adopted during specimen collection
and sputum induction should be avoided.
The WHO & other organizations have issued the following
general recommendations:
I. Avoid close contact with subjects suffering from acute
respiratory infections.
II. Wash your hands frequently, especially after contact with
infected people or their environment.
III. Avoid unprotected contact with farm or wild animals.
IV. People with symptoms of acute airway infection should
keep their distance, cover coughs or sneezes with disposal
tissues or clothes and wash their hands.
V. Individuals that are immune-compromised should avoid
public gatherings.
VI. The most important strategy is to frequently wash the hands
and use portable hand sanitizer and avoid contact with their
face & mouth after interacting with a possibly
contaminated environment.
VII. Health Care workers caring for infected individuals should
utilize contact & airborne precautions to include PPE such
as N95 or FFP3 masks, eye protection, gowns & gloves to
prevent transmission of pathogens. [21]
The corona virus disease (COVID-19) has been identified as the
cause of an outbreak of respiratory illness in Wuhan, Hubei
Province, China beginning in December 2019. As of 31 January
2020, this epidemic had spread to 19 countries with 11791
confirmed cases, including 213 deaths. A study of the first 41
cases of confirmed COVID-19, published in January 2020 in
The Lancet, reported the earliest date of onset of symptoms as 1
December 2019.Official publications from the WHO reported
9
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
the earliest onset of symptoms as 8 December 2019.Human-to-
human transmission was confirmed by the WHO and Chinese
authorities by 20 January 2020.In May 2020, George Gao, the
director of the Chinese Centre for Disease control and
prevention (CDC), said animal samples collected from the
seafood market had tested negative for the virus, indicating that
the market was the site of an early super spreading event, but it
was not the site of the initial outbreak.
By December 2019, the spread of infection was almost
entirely driven by human-to-human transmission. The
number of corona virus cases in Hubei gradually increased,
reaching 60 by 20 December and at least 266 by 31
December. The Wuhan Municipal Health Commission
made the first public announcement of a pneumonia
outbreak of unknown cause on 31 December, confirming
27 cases enough to trigger an investigation. A report in The
Lancet on 24 January indicated human transmission,
strongly recommended personal protective equipment for
health workers, and said testing for the virus was essential
due to its "pandemic potential". On 30 January, the WHO
declared the corona virus a “Public Health Emergency of
International Concern”. By this time, the outbreak spread
by a factor of 100 to 200 times.
On 31 January 2020, Italy had its first confirmed cases, two
tourists from China. As of 13 March 2020, the WHO
considered Europe the active centre of the pandemic. On 19
March 2020, Italy overtook China as the country with the most
deaths. By 26 March, the United States had overtaken China
and Italy with the highest number of confirmed cases in the
world. On 11 June 2020, after 55 days without a locally
transmitted case, Beijing reported the first COVID-19 case,
followed by two more cases on 12 June. By 15 June, 79 cases
were officially confirmed. Most of these patients went to
Xinfadi Wholesale Market. As per WHO: 17-12-2021;
10
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
Prevalence of Corona Virus Disease (COVID-19) in the world
are 271,963,258 cases, deaths are 5,331,019. On 18-12-2021;
incidence was 18993. On 16-12-2021; 8,337,664,456 vaccine
doses have been administered. [22]
The COVID-19 pandemic in India is part of the worldwide
pandemic of corona virus disease 2019 (COVID-19) caused
by severe acute respiratory syndrome corona virus 2
(SARS-CoV-2) with a rise of 127 million reported case,
71.7 million recoveries and 2.78 million deaths globally as
in March 28, 2021. The first case of COVID-19 in India,
which originated from China, was reported on 30 January
2020. India currently has more than 11.9 million reported
cases of COVID-19 infection and more than 161k deaths as
of March 28, 2021.The new COVID-19 cases in India are
over 60,000 cases reported per day as in mid-March, 2021.
On 18-12-2021 prevalence was 34,733,194 cases. On 6-12-
2021 1,294,608,045 vaccine doses have been administered.
[23]
In union territory of Jammu and Kashmir, two suspected
cases with high virus load were detected and isolated on 4
March in Government Medical College, Jammu. One of
them became the first confirmed positive case on 9 March
2020. Both individuals had a travel history to Iran. As of 28
March 2021; total numbers of positive cases in Jammu and
Kashmir were 129k. This includes, 126k successful
recoveries/discharges and 1984 deaths. With a testing rate
over 10,000 per million, Jammu & Kashmir is now leading
all the states in the country in testing. 13 June 2021, total
no. Of active cases was 16284, successful recoveries/
discharges was 286180 and deaths was 4174. Total vaccine
doses administered are 36, 46,922. On 16-12-2021;
Confirmed cases was 3, 23499, Active cases was 1229,
Recovered case was 3, 17,872 and Deaths was 4398. On 25
August 202, nearly 16.5 lakh people received 2 doses of
11
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
vaccine. On 20 September 2021, 1 crore vaccine doses was
administered. On 14 October 2021 1.4 crore doses of
Vaccine have been administered so far in J and K. [24]
12
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
14
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
15
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
17
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
OPERATIONAL DEFINITION:
Impact: In this study, it refers to the outcome of the Structured
Teaching Program (STP) in improving the knowledge of Corona
Virus Disease (COVID-19) among the GNM students under the
study.
19
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
ASSUMPTIONS:
1. The General Nursing Midwifery (GNM) students have
significantly inadequate knowledge regarding the Corona
Virus Disease (COVID-19), because of their academic
level.
2. The Structured Teaching Program (STP) will enhance the
knowledge of the General Nursing Midwifery (GNM)
students regarding the Corona Virus Disease (COVID-
19).
3. Appropriate knowledge regarding the Corona Virus
Disease (COVID-19) can reduce the incidence of the
Corona Virus Disease (COVID-19)---new cases.
Pilot study.
23
CHPATER
INTRODUCTION
BNBBBBFGFYTFT
1
and information that are released from the system into the
environment. Here, it refers to the assessment of the
performance of the GNM students to the Structured
Teaching Program and to find out whether there is any
evidence of the desired change in the knowledge of the
GNM students.
SUMMARY
This chapter dealt with the introduction, need for the study,
and statement of problem, operational definitions,
assumptions, hypothesis, delimitations and conceptual
framework.
24
(Fig. 01) CONCEPTUAL FRAMEWORK BASED ON THE
SYSTEM MODEL
THROUGHTP OUTPUT
INPUT UT/
Knowledge
D
Development of the structured
e
knowledge questionnaire regarding
m
the knowledge of Corona Virus Disease
o
(COVID-19)
g
r Development of STP
a
Validation of the tool and intervention
p
by the experts
h Target
i Pilot study group
c
Pre-test of the knowledge
G N
FEEDBACK
KEY
Administra Administrati
on of STP is
tion of STP not effective
not in our is effective
study
19